Short answer
Regeneron Pharmaceuticals (REGN) filed its Q1 2025 10-Q quarterly report on Apr 29, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $3.0B (down 3.7% year over year) with net income of $809M.
Q1 2025 key financials · XBRL
- Revenue
- $3.0B
- −3.7% YoY
- Net income
- $809M
- +12.0% YoY
- Operating margin
- 19.5%
- EPS (diluted)
- $7.27
- +15.9% YoY
Source: XBRL data from the Regeneron Pharmaceuticals (REGN) Q1 2025 10-Q on SEC EDGAR. USD.
Regeneron Pharmaceuticals Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk added: EYLEA HD FDA approval in August 2023 triggered dependence risk on EYLEA HD commercialization success
- Updated risk: EYLEA U.S. net sales declined 39% YoY due to increased competition and market pressures, impacting revenue materially
- Regulatory risk: Failure to comply with Medicaid Drug Rebate program could lead to penalties, sanctions, and additional reimbursement requirements
- Operational risk: Manufacturing capacity insufficient to meet rising demand for EYLEA/EYLEA HD, dependence on collaborators and contract manufacturers increasing
- Financial risk: Aggregate EYLEA HD and EYLEA U.S. sales represent 34% of total revenues in Q1 2025, concentration risk on these products significant
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Regeneron Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.